Market and Product Forecasts: Top 10 Neurology Brands 2011–21

Published by: Datamonitor

Published: Sep. 1, 2012

Table of Contents

Overview
Catalyst
Summary

About Datamonitor Healthcare
About the Central Nervous System pharmaceutical analysis team

Executive Summary
Datamonitor key findings

Market Definition
Market definition for neurology therapies
Forecast methodology and assumptions
Additional forecast methodology

Market Overview and Context
Neurology therapy brands included in Datamonitor’s analysis
Seven major market top 10 neurology therapy brands
US top 10 neurology therapy brands
Japan top 10 neurology therapy brands
Five major EU markets top 10 neurology therapy brands

Currently Marketed Product Forecasts
Brand dynamics
Copaxone (glatiramer acetate; Teva)
Lyrica (pregabalin; Pfizer)
Avonex (interferon beta-1a; Biogen Idec)
Aricept (donepezil; Eisai/Pfizer)
Rebif (interferon beta-1a; Merck Serono/Pfizer)
Namenda (memantine; Forest/Merz/Lundbeck)
Gilenya (fingolimod; Novartis)

Pipeline Product Forecasts
Brand dynamics
Solanezumab (Eli Lilly)
BG-12 (dimethyl fumarate; Biogen Idec)
Lemtrada (alemtuzumab; Sanofi)
Suvorexant (Merck & Co.)

Bibliography
Websites

Appendix
Forecast methodology
About Datamonitor

Abstract

The diverse field of neurology hosts numerous disorders with substantial unmet clinical need, creating a complex but lucrative market. Considerable rewards are available for the manufacturers of successful neurological therapies, as effective lifecycle management and the pitfalls of R&D can insulate brands from competition. The neurology market is set to remain an attractive long-term prospect.

Neurology brands were worth a combined $30.6bn in the seven major markets in 2011, with the top 10 neurology brands achieving combined sales of $19.2bn. Collectively, sales of branded multiple sclerosis therapies totaled $11.3bn, with sales dwarfing other major neurological disorders, such as epilepsy, Alzheimer’s disease, and Parkinson’s disease.

The US neurology market is the largest, accommodating six blockbuster brands. The Japanese market is less developed, although numerous established brands in Western markets have recently been introduced. A slight decline in the 5EU is expected, as pricing pressure and increased competition from generics outweigh any growth provided by new products.

Datamonitor expects several leading neurology brands to remain lucrative, even after patent expiry. The molecular complexity of MS therapies, being either biologics or synthetic peptides, provides a barrier for generics companies. Lyrica and Namenda will benefit from Japan launches and the added exclusivity that their once-daily versions provide.

Note: This report is delivered as a zip.

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 400,000 market research reports, company profiles and country profiles from over 720 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.